Across separate registration trials, retatrutide produced the largest average weight loss of the three: roughly 24.2% at 48 weeks in its phase 2 study, rising to 28.3% in the 2026 TRIUMPH-1 phase 3 trial. Tirzepatide reached 22.5% in SURMOUNT-1, and semaglutide 14.9% in STEP 1.
What separates these three drugs?
All three quiet appetite by acting on gut-hormone pathways, but they hit a different number of targets. Semaglutide (Ozempic, Wegovy) is a single GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1 and GIP agonist. Retatrutide adds a third lever, glucagon, making it the first triple agonist to reach late-stage obesity trials.
More targets has, so far, tracked with more weight loss. But semaglutide and tirzepatide are FDA-approved and widely prescribed, while retatrutide is still investigational. The "better" drug depends on whether you weight raw efficacy or actual access.
How much weight does each one cause you to lose?
These figures come from different trials with different patients and durations, so treat them as directional rather than a clean head-to-head. The numbers below use each study's efficacy estimand (the on-treatment result).
| Drug | Trial | Top dose | Duration | Mean weight loss |
|---|---|---|---|---|
| Semaglutide 2.4 mg | STEP 1 | 2.4 mg/wk | 68 wk | 14.9% |
| Tirzepatide | SURMOUNT-1 | 15 mg/wk | 72 wk | 22.5% |
| Retatrutide (phase 2) | Jastreboff 2023 | 12 mg/wk | 48 wk | 24.2% |
| Retatrutide (phase 3) | TRIUMPH-1 | 12 mg/wk | 80 wk | 28.3% |
In TRIUMPH-1, about 45% of participants on the top dose lost at least 30% of body weight, a threshold that approaches some bariatric surgery outcomes. For the only true apples-to-apples comparison, see the head-to-head section below.
How do the mechanisms actually differ?
GLP-1 agonism slows gastric emptying and signals fullness to the brain. That alone drives semaglutide's results. GIP agonism, added by tirzepatide, appears to improve how the body handles fat and may blunt nausea, letting patients tolerate higher effective doses.
Glucagon, retatrutide's third target, sounds counterintuitive because glucagon usually raises blood sugar. At the right balance, though, it increases energy expenditure and pushes the liver to burn fat. The trade-off is a modest rise in heart rate and the need for careful dose escalation. Our explainer on how the retatrutide triple agonist works breaks down the receptor balance in more detail.
What does the only head-to-head trial show?
The cleanest comparison is semaglutide versus tirzepatide, tested directly in SURMOUNT-5. Over 72 weeks, tirzepatide produced about 20.2% weight loss versus 13.7% for semaglutide in the same population, confirming the gap seen across separate trials. No published head-to-head pits retatrutide against either drug yet, so its lead rests on cross-trial comparison only.
This distinction matters when you read marketing claims. A direct trial like SURMOUNT-5 controls for differences in patient mix, trial length, and analysis method, so the tirzepatide-over-semaglutide gap is well established. Retatrutide's apparent lead over both is drawn from comparing one trial to another, which is suggestive but not definitive. Until a head-to-head trial runs, treat retatrutide's numbers as the most promising signal in the class rather than a confirmed ranking.
How do dosing and titration compare?
All three are once-weekly subcutaneous injections that start low and step up to limit nausea.
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Schedule | Weekly | Weekly | Weekly |
| Start dose | 0.25 mg | 2.5 mg | 2 mg |
| Top trial dose | 2.4 mg | 15 mg | 12 mg |
| Titration | ~16+ wk | ~20 wk | ~12-16 wk |
Faster escalation tends to mean more early gut side effects, so most protocols hold each step for at least four weeks. Our guide on when to increase a GLP-1 dose covers the signals that you are ready to move up.
Which one can you actually get in 2026?
This is where the ranking flips. Semaglutide and tirzepatide are FDA-approved and available by prescription through pharmacies and telehealth. Retatrutide is not approved; it cleared TRIUMPH-1 in May 2026 but still needs its diabetes and cardiovascular trials and an FDA review. If you want the strongest option today, tirzepatide is the most potent approved drug; see which GLP-1 is best for weight loss for the full decision matrix.
How do side effects compare?
The side-effect profile is similar in kind across all three, dominated by nausea, vomiting, diarrhea, and constipation that peak during titration. Retatrutide and tirzepatide both raise heart rate modestly. Retatrutide's glucagon activity makes dose escalation the period to watch most closely. For management tactics that apply across the class, see our breakdown of why GLP-1 nausea happens and what helps.
There is a rough trade-off worth naming: the drugs that produce more weight loss also tend to produce more intense early symptoms simply because they reach higher effective doses. That does not mean semaglutide is "safer" so much as gentler to titrate for many people, while the higher-potency options ask for more patience during the climb. Tolerance is individual, though, and some people sail through tirzepatide while struggling on semaglutide. The class also shares contraindications, including a personal or family history of medullary thyroid cancer, which is why a prescriber screens before starting any of them.
So which is better?
If the only question is raw weight loss, retatrutide leads on the data we have, tirzepatide is the strongest approved drug, and semaglutide is the most established. For most people in 2026, the practical choice is between the two approved options, with retatrutide a likely future upgrade once it clears regulatory review.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- Eli Lilly. Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1), May 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Aronne LJ, et al. Tirzepatide vs Semaglutide for Obesity (SURMOUNT-5). New England Journal of Medicine, 2025. https://www.nejm.org/doi/abs/10.1056/NEJMoa2416394
Frequently Asked Questions
Is retatrutide better than tirzepatide and semaglutide?
On trial weight loss it produced the highest average reduction (28.3% in TRIUMPH-1), but it is not yet FDA-approved, so it is not better in the sense of being something you can obtain and use today.
Can you switch between these drugs?
Switching between approved options is common and usually done by a prescriber who restarts titration rather than matching doses directly, because milligram amounts are not equivalent across the three.
Which has the fewest side effects?
The categories of side effects are similar. Semaglutide has the longest real-world track record, while the higher-potency drugs trade more weight loss for somewhat more intense titration symptoms.
Will retatrutide replace the others?
It may become the most potent option if approved, but cost, access, and individual tolerance will keep all three relevant rather than producing a single winner.
This article is educational and not medical advice; treatment decisions should be made with a licensed clinician.
